Pull to refresh
Logo
What Changed
Following Why Sign Up
Karyopharm files for bankruptcy to sell itself to Ayrmid

Karyopharm files for bankruptcy to sell itself to Ayrmid

Money Moves

The maker of the blood cancer drug Xpovio is running a court-supervised auction, but its shares are leaving Nasdaq and the plan pays stockholders nothing.

7 days ago: Nasdaq moves to delist Karyopharm

Overview

Updated 4 days ago

Karyopharm Therapeutics filed for Chapter 11 on November 2, 2026, naming Ayrmid Ltd. as the lead bidder for its assets. A bankruptcy judge has approved bidding rules that set a December 16 deadline for competing offers, an auction on December 21 and a sale hearing on January 11, 2027.

Nasdaq told Karyopharm on November 4 that it will delist the stock, with trading suspended November 11 and shares expected to trade over the counter as KPTIQ. The reorganization plan gives common and preferred stockholders nothing, and the company says existing equity will have no value. Karyopharm also said 48-week myelofibrosis data from its SENTRY trial will get an oral presentation at the ASH hematology meeting.

Why it matters

A drug that reached patients and still couldn't cover its costs shows how thin the margin is between a commercial biotech and insolvency.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$115M
Net Xpovio sales, 2025
Annual net product revenue from the company's only marketed drug.
$196M
Net loss, 2025
Annual loss reported in the company's 2025 annual report.
$1.8B
Accumulated deficit
Cumulative losses carried on the balance sheet at the time of filing.
$55M
Debtor-in-possession financing
Committed by existing secured lenders to fund operations during Chapter 11.
$0
Payout to stockholders
The plan of reorganization gives holders of common and preferred stock no payment or distribution.
Dec 21
Auction date
Court-approved date for an auction, held only if a qualified competing bid arrives.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

JW
Joe Wiley
Chief executive of Ayrmid Ltd., the lead bidder
Leading the acquisition of Karyopharm through Chapter 11

Organizations Involved

Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
Commercial-stage pharmaceutical company
In Chapter 11 and leaving Nasdaq; shares expected to trade over the counter as KPTIQ from November 11

Massachusetts drugmaker whose only marketed product is the blood cancer drug Xpovio.
AL
Ayrmid Ltd.
Pharmaceutical holding company
Court-approved stalking horse bidder; auction set for December 21, 2026 if a competing bid arrives

Parent of cell therapy maker Gamida Cell, bidding to add Karyopharm's blood cancer drug to its portfolio.
Gamida Cell
Gamida Cell
Cell therapy developer
Subsidiary of Ayrmid; would absorb Karyopharm if the deal closes

Blood cancer cell therapy company whose parent is bidding for Karyopharm.
BC
U.S. Bankruptcy Court for the Southern District of Texas
Federal court
Overseeing the Chapter 11 case and a court-approved auction

Court handling Karyopharm's Chapter 11 case, docketed as No. 26-90827.

Timeline

2019 November 2026

8 events Latest: 7 days ago
Tap a bar to jump to that date

  1. Nasdaq moves to delist Karyopharm

    Latest Legal

    Nasdaq notified the company it will delist the stock, citing the bankruptcy filing and the outlook for existing shareholders. Karyopharm said it will not appeal; trading stops November 11 and shares are expected to trade over the counter as KPTIQ.

  2. SENTRY data picked for ASH oral presentation

    Clinical

    Karyopharm said 48-week results from its Phase 3 SENTRY and Phase 2 SENTRY-2 myelofibrosis trials will be presented orally at ASH 2026.

  3. Chapter 11 filing and Ayrmid merger

    Legal

    Karyopharm files in the Southern District of Texas with Ayrmid as lead bidder and $55 million in lender financing.

  4. Court approves bidding procedures

    Legal

    The bankruptcy court approved sale procedures and designated Ayrmid as stalking horse bidder, setting a December 16 bid deadline, a December 21 auction and a January 11, 2027 sale hearing.

  5. Lenders grant forbearance

    Legal

    Karyopharm skips a $15.8 million principal payment and signs a forbearance deal through October 15.

  6. Cash dwindles, interest skipped

    Financial

    Company holds $55 million in cash and misses interest payments on its convertible notes.

  7. Losses outrun sales

    Financial

    Annual report shows $115 million in net Xpovio sales against $196 million in losses.

  8. Xpovio reaches the market

    Approval

    U.S. regulators approve Karyopharm's drug for multiple myeloma; a lymphoma clearance follows.

Scenarios

1

Ayrmid wins the auction and closes the merger

Likely Resolves by Q1 2027

Discussed by: Karyopharm and Ayrmid, in their joint announcement and court filings

No rival tops Ayrmid's stalking horse offer. The court approves the sale, the Chapter 11 plan is confirmed, and the transaction closes in the first quarter of 2027. Xpovio continues under new ownership, folded into a combined hematology business with Gamida Cell.

2

A rival bid tops Ayrmid at auction

Possible Resolves by Jan 31, 2027

Discussed by: Bankruptcy observers tracking the stalking horse process

The court-approved bidding procedures draw a competing offer above Ayrmid's. An auction sets the final price, and a different buyer, possibly a larger hematology company, takes Xpovio. Ayrmid's bid protections would entitle it to a breakup fee if it loses.

3

FDA clears Xpovio in myelofibrosis, lifting the sale price

Possible Resolves by Q2 2027

Discussed by: Karyopharm, which has a pending supplemental application for the combination

Regulators approve selinexor with ruxolitinib for myelofibrosis, adding a new patient population and revenue line. The clearance lands during the bankruptcy and raises what bidders will pay, or strengthens the reorganized company's case.

4

No qualified bid, assets sold off piecemeal

Unlikely Resolves by Q1 2027

Discussed by: Creditors and restructuring analysts weighing a liquidation path

The auction produces no qualified offer, or the lead bidder walks. The case converts to a Chapter 7 liquidation, Xpovio changes hands in fragments, and shareholders recover nothing. Ayrmid's chief executive has said the deal is not intended to end in liquidation.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

November 2014

Dendreon bankruptcy (2014)

Dendreon won approval in April 2010 for Provenge, the first therapeutic cancer vaccine, priced at $93,000 per course. Manufacturing constraints and slow reimbursement kept sales far below forecasts. The company filed for Chapter 11 in November 2014 and sold its assets to Sanofi.

Then

Provenge changed hands at a fraction of Dendreon's former valuation, and shareholders were wiped out.

Now

It became the standard cautionary tale for cancer therapies whose manufacturing or reimbursement costs outrun their sales.

Why this matters now

Karyopharm's Xpovio is a conventional pill, not a bespoke therapy, but the pattern matches: approval without enough revenue to cover the cost of getting there.

October 2013 - February 2017

Ariad Pharmaceuticals safety crisis (2013-2017)

Ariad's leukemia drug Iclusig was pulled from the U.S. market in October 2013 after reports of serious blood clots and heart problems. Regulators let it return months later with a narrower label and a boxed warning. Ariad rebuilt sales, and Takeda acquired the company in February 2017 for $5.2 billion.

Then

The withdrawal briefly threatened the company's survival and crushed its stock.

Now

A narrower label still supported a multibillion-dollar acquisition, showing a single niche cancer drug can carry a company if the economics work.

Why this matters now

It shows a label setback need not be fatal. Karyopharm's problem is different: demand and debt, not a safety recall, and its debt came due before a recovery.

Sources

(10)
+4
BioPharma Dive Karyopharm Therapeutics U.S. Securities and Exchange Commission Bankruptcy Observer Dealroom Investing.com Biotech Insider Boston Business Journal Latham & Watkins U.S. Securities and Exchange Commission